Anti‐Hyperuricemic, Nephroprotective, and Gut Microbiota Regulative Effects of Separated Hydrolysate of α‐Lactalbumin on Potassium Oxonate‐ and Hypoxanthine‐Induced Hyperuricemic Mice

Scope This study aims to investigate the anti‐hyperuricemic and nephroprotective effects and the potential mechanisms of the separated gastrointestinal hydrolysates of α‐lactalbumin on hyperuricemic mice. Methods and results The gastrointestinal hydrolysate of α‐lactalbumin, the hydrolysate fraction with molecular weight (MW) < 3 kDa (LH‐3k), and the fragments with smallest MW among LH‐3K harvested through dextran gel chromatography (F5) are used. Hyperuricemia mice are induced via daily oral gavage of potassium oxonate and hypoxanthine. F5 displays the highest in vitro xanthine oxidase (XO) inhibition among all the fractions separated from LH‐3k. Oral administration of F5 significantly reduces the levels of serum uric acid (UA), creatinine, and urea nitrogen. F5 treatment could ameliorate kidney injury through alleviating oxidative stress and inflammation. F5 alleviates hyperuricemia in mice by inhibiting hepatic XO activity and regulating the expression of renal urate transporters. Gut microbiota analysis illustrates that F5 administration increases the abundance of some SCFAs producers, and inhibits the growth of hyperuricemia and inflammation associated genera. LH‐3k exhibits similar effects but does not show significance as those of the F5 fraction. Conclusion The anti‐hyperuricemia and nephroprotective functions of F5 are mediated by inhibiting hepatic XO activity, ameliorating oxidative stress and inflammation, regulating renal urate transporters, and modulating the gut microbiota in hyperuricemic mice.